ClinicalTrials.gg
CompletedNCT05350969HF-REVERTUpdated Aug 26, 2026Results posted

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

A Phase 2 interventional study of CDR132L and Placebo to CDR132L in Myocardial Infarction, Acute and Heart Failure, Left Sided, sponsored by Cardior Pharmaceuticals GmbH. Completed at 49 sites in 8 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Cardior Pharmaceuticals GmbH (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 21 under way, 5 of them phase 3. Myocardial Infarction · Poland.

Enrollment
50th of 77
294 · median 1,012
Started
2022
with 1 other
Phase 2
14 of 89
2 open now
Registered
71st of 89
by date

Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 50th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 in phase 2, and was the 71st registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Myocardial Infarction with a site in Poland, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12.

Two dosages of CDR132L will be tested against placebo on their effects on patients, who just had a heart attack in addition to standard care. The aim of the study is to show that CDR132L is safe and effective to improve heart failure in such patients.

03

Conditions studied

  • Myocardial Infarction, Acute
  • Heart Failure, Left Sided
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female patients, aged ≥ 30 to ≤ 80 years at the date of signing which is defined as the beginning of the Screening Period.
  2. Spontaneous acute mycardial infarction (AMI) (type I) based on the universal MI definition with randomization to occur no later than 14 days after index event diagnosis.
  3. Patient with a ≤ 45% as measured by ECHO after MI diagnosis (STEMI or NSTEMI).
  4. Patient with previous MI events in history can be included.
  5. Patient with body weight of ≤ 120 kg.
  6. N-terminal pro B-type natriuretic peptide level ≥ 125 pg/ml and \< 8000 pg/ml at screening.
  7. Patient with STEMI/NSTEMI who underwent percutaneous coronary intervention for this event.

Exclusion Criteria:

  1. A woman of (WOCBP).
  2. Patient with HF of non-ischemic origin; e.g., myocarditis, alcoholic cardiomyopathy.
  3. Patient with (NYHA) class IV at screening or randomization.
  4. Patient has any planned cardiac intervention (angiogram without angioplasty is acceptable) or any other planned surgery after the Screening Period.
  5. Patient has severe valvular heart disease.
  6. Patient has systolic BP \< 90 mmHg or > 180 mmHg, diastolic BP \< 50 mmHg or > 110 mmHg, and/or heart rate \< 50 or > 100 beats/minute at screening or randomization.
  7. Patient with an estimated \< 30 mL/min/1.73 m2 or on dialysis.
  8. Patient with hepatic insufficiency classified as B or C.
  9. Patient has medical history of disease(s) affecting the blood-brain-barrier, e.g., stroke within 6 months or multiple sclerosis.
  10. Patient has medical history of bleeding disorders or has thrombocytopenia ( \< 100,000/μL).
  11. Patient has poorly controlled diabetes as determined by the Investigator.
  12. Patient has a history or presence of any of the following cardiac conditions: known structural cardiac abnormalities beyond HF, family history of long syndrome, cardiac syncope, or recurrent, idiopathic syncope.
  13. Any abnormalities, at the discretion of the Investigator, in rhythm, conduction, or morphology of resting that pose an additional safety risk to patients.
  14. Patient with active "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" infection confirmed as per the local testing guidelines at screening.
  15. Patient is not to be enrolled into the study if they received any prohibited therapy within 3 months of screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    CDR132L 5 mg

    CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57

    Drug: CDR132L

  • Experimental
    CDR132L 10 mg

    CDR132L 10 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57

    Drug: CDR132L

  • Placebo comparator
    Placebo

    Placebo intravenous in single dose on Day 1, Day 29 and Day 57

    Drug: Placebo to CDR132L

Interventions

  • CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

  • DrugPlacebo to CDR132L

    Placebo to CDR132L

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6

    Percent change from baseline in LVESVI at Month 6 is presented. LVESVI is considered one of the standard echocardiography (ECHO) markers for assessing risks in ischemic heart failure (HF). The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 6

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    Number of TEAEs were presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment.

    Time frame: Up to 12 months

  2. Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Number of TESAEs are presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: a) results in death, b) is life-threatening, c) requires inpatient hospitalization or prolongation of existing hospitalization, d) results in persistent disability/incapacity, e) is a congenital anomaly/birth defect, f) other situations where medical or scientific judgement should be excercised.

    Time frame: Up to 12 months

  3. Number of Participants With Abnormalities in Clinically Relevant Laboratory Assessments

    Number of participants with abnormalities in clinically relevant laboratory assessments up to month 6 is presented. Laboratory investigation included hematology, chemistry, coagulation and urinalysis parameters. Clinical relevance was decided by the investigator.

    Time frame: At month 6

  4. Number of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters

    Number of participants with clinically relevant laboratory abnormalities in vital signs parameters on month 12 is presented. Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate. Clinical relevance was decided by the investigator.

    Time frame: At month 12

  5. Number of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters

    Number of participants with clinically relevant laboratory abnormalities in ECG parameters at month 12 is presented. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Pulse Rate, QRS, QT interval. Clinical relevance was decided by the investigator.

    Time frame: At month 12

  6. Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 3

    Absolute change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D echocardiography (ECHO) was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 3

  7. Absolute Change From Baseline in LVEF at Month 6

    Absolute change from baseline in LVEF at month 6 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 6

  8. Absolute Change From Baseline in LVEF at Month 12

    Absolute change from baseline in LVEF at month 12 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 12

  9. Relative Change From Baseline in LVEF at Month 3

    Relative change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 3

  10. Relative Change From Baseline in LVEF at Month 6

    Relative change from baseline in LVEF at month 6 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 6

  11. Relative Change From Baseline in LVEF at Month 12

    Relative change from baseline in LVEF at month 12 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

    Time frame: Baseline (Day 1), Month 12

  12. Absolute Change From Baseline in LVESVI at Month 3

    Absolute change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 3

  13. Absolute Change From Baseline in LVESVI at Month 6

    Absolute change from baseline in LVESVI at month 6 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 6

  14. Absolute Change From Baseline in LVESVI at Month 12

    Absolute change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 12

  15. Relative Change From Baseline in LVESVI at Month 3

    Relative change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 3

  16. Relative Change From Baseline in LVESVI at Month 12

    Relative change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

    Time frame: Baseline (Day 1), Month 12

  17. Absolute Change From Baseline in Troponin T at Month 3

    Absolute change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by high-sensitivity cardiac troponin (hs-cTn) assays.

    Time frame: Baseline (Day 1), Month 3

  18. Absolute Change From Baseline in Troponin T at Month 6

    Absolute change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.

    Time frame: Baseline (Day 1), Month 6

  19. Absolute Change From Baseline in Troponin T at Month 12

    Absolute change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.

    Time frame: Baseline (Day 1), Month 12

  20. Relative Change From Baseline in Troponin T at Month 3

    Relative change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by hs-cTn assays.

    Time frame: Baseline (Day 1), Month 3

  21. Relative Change From Baseline in Troponin T at Month 6

    Relative change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.

    Time frame: Baseline (Day 1), Month 6

  22. Relative Change From Baseline in Troponin T at Month 12

    Relative change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.

    Time frame: Baseline (Day 1), Month 12

  23. Absolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1

    Absolute change from baseline in NT-proBNP at month 1 is presented.

    Time frame: Baseline (Day 1), Month 1

  24. Absolute Change From Baseline in NT-proBNP at Month 2

    Absolute change from baseline in NT-proBNP at month 2 is presented.

    Time frame: Baseline (Day 1), Month 2

  25. Absolute Change From Baseline in NT-proBNP at Month 3

    Absolute change from baseline in NT-proBNP at month 3 is presented.

    Time frame: Baseline (Day 1), Month 3

  26. Absolute Change From Baseline in NT-proBNP at Month 6

    Absolute change from baseline in NT-proBNP at month 6 is presented.

    Time frame: Baseline (Day 1), Month 6

  27. Absolute Change From Baseline in NT-proBNP at Month 12

    Absolute change from baseline in NT-proBNP at month 12 is presented.

    Time frame: Baseline (Day 1), Month 12

  28. Relative Change From Baseline in NT-proBNP at Month 1

    Relative change from baseline in NT-proBNP at month 1 is presented.

    Time frame: Baseline (Day 1), Month 1

  29. Relative Change From Baseline in NT-proBNP at Month 2

    Relative change from baseline in NT-proBNP at month 2 is presented.

    Time frame: Baseline (Day 1), Month 2

  30. Relative Change From Baseline in NT-proBNP at Month 3

    Relative change from baseline in NT-proBNP at month 3 is presented.

    Time frame: Baseline (Day 1), Month 3

  31. Relative Change From Baseline in NT-proBNP at Month 6

    Relative change from baseline in NT-proBNP at month 6 is presented.

    Time frame: Baseline (Day 1), Month 6

  32. Relative Change From Baseline in NT-proBNP at Month 12

    Relative change from baseline in NT-proBNP at month 12 is presented.

    Time frame: Baseline (Day 1), Month 12

  33. Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 6

    Absolute change from baseline in mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score (overall summary score) at month 6 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Sum-mary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.

    Time frame: Baseline (Day 1), Month 6

  34. Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 12

    Absolute change from baseline in mean KCCQ score (overall summary score) at month 12 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Summary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.

    Time frame: Baseline (Day 1), Month 12

  35. Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 6

    Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 6

  36. Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 12

    Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 12

  37. Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 6

    Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 6

  38. Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 12

    Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 12

  39. Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 6

    Absolute change from baseline in KCCQ subdomain score (quality of life) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 6

  40. Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 12

    Absolute change from baseline in KCCQ subdomain score (quality of life) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.

    Time frame: Baseline (Day 1), Month 12

07

Results

Posted Aug 26, 2026

Participant flow

The trial was conducted in 8 countries (Netherlands, Spain, Germany, Czech Republic, Poland, United Kingdom, Greece, and Hungary).

Participant flow — Overall Study
MilestonePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Started989898
Modified intent-to-treat (mitt) analysis set909496
Safety analysis set (saf)919495
Completed828691
Not completed16127
Withdrew: Withdrawal by subject894
Withdrew: Subject non-compliance with study schedule100
Withdrew: Protocol violation101
Withdrew: Physician decision120
Withdrew: Lost to follow-up010
Withdrew: Death501
Withdrew: Adverse event001

Outcome measures

SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

Number of TEAEs were presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment.

Time frame:
Up to 12 months
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Number of Treatment Emergent Adverse Events (TEAEs)81116120
SecondaryNumber of Treatment Emergent Serious Adverse Events (TESAEs)

Number of TESAEs are presented. TEAEs were defined as AEs that first occurred or worsened in severity after the first administration of study treatment and prior to 30 days after the last administration of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose: a) results in death, b) is life-threatening, c) requires inpatient hospitalization or prolongation of existing hospitalization, d) results in persistent disability/incapacity, e) is a congenital anomaly/birth defect, f) other situations where medical or scientific judgement should be excercised.

Time frame:
Up to 12 months
Reported as:
Number · Events
Number of Treatment Emergent Serious Adverse Events (TESAEs)
EventsPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Number of Treatment Emergent Serious Adverse Events (TESAEs)101310
SecondaryNumber of Participants With Abnormalities in Clinically Relevant Laboratory Assessments

Number of participants with abnormalities in clinically relevant laboratory assessments up to month 6 is presented. Laboratory investigation included hematology, chemistry, coagulation and urinalysis parameters. Clinical relevance was decided by the investigator.

Time frame:
At month 6
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Clinically Relevant Laboratory Assessments
ParticipantsPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Number of Participants With Abnormalities in Clinically Relevant Laboratory Assessments000
SecondaryNumber of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters

Number of participants with clinically relevant laboratory abnormalities in vital signs parameters on month 12 is presented. Vital signs included oral body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate. Clinical relevance was decided by the investigator.

Time frame:
At month 12
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters
ParticipantsPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Number of Participants With Clinically Relevant Laboratory Abnormalities in Vital Signs Parameters000
SecondaryNumber of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters

Number of participants with clinically relevant laboratory abnormalities in ECG parameters at month 12 is presented. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. The parameters included heart rate (HR), Pulse Rate, QRS, QT interval. Clinical relevance was decided by the investigator.

Time frame:
At month 12
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters
ParticipantsPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Number of Participants With Clinically Relevant Laboratory Abnormalities in ECG Parameters000
SecondaryAbsolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 3

Absolute change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D echocardiography (ECHO) was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · Percentage of LVEF
Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 3
Percentage of LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 37.079 ± 9.12517.249 ± 8.23538.158 ± 8.1040
SecondaryAbsolute Change From Baseline in LVEF at Month 6

Absolute change from baseline in LVEF at month 6 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Percentage of LVEF
Absolute Change From Baseline in LVEF at Month 6
Percentage of LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in LVEF at Month 67.204 ± 8.98277.702 ± 8.79038.345 ± 8.9602
SecondaryAbsolute Change From Baseline in LVEF at Month 12

Absolute change from baseline in LVEF at month 12 is reported. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Percentage of LVEF
Absolute Change From Baseline in LVEF at Month 12
Percentage of LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in LVEF at Month 127.832 ± 10.21497.238 ± 9.65059.996 ± 10.3128
SecondaryRelative Change From Baseline in LVEF at Month 3

Relative change from baseline in LVEF at month 3 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · Percentage change in LVEF
Relative Change From Baseline in LVEF at Month 3
Percentage change in LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in LVEF at Month 320.344 ± 27.978521.416 ± 26.819726.864 ± 43.5875
SecondaryRelative Change From Baseline in LVEF at Month 6

Relative change from baseline in LVEF at month 6 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Percentage change in LVEF
Relative Change From Baseline in LVEF at Month 6
Percentage change in LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in LVEF at Month 620.702 ± 26.406523.358 ± 30.449027.218 ± 45.2933
SecondaryRelative Change From Baseline in LVEF at Month 12

Relative change from baseline in LVEF at month 12 is presented. LVEF is an established method for evaluation of left ventricular systolic function. A 2D ECHO was performed in the ECHO central laboratory by trained personnel to assess LVEF. Contrast ECHO was available as an option to enhance image quality.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Percentage change in LVEF
Relative Change From Baseline in LVEF at Month 12
Percentage change in LVEFPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in LVEF at Month 1222.564 ± 30.271922.745 ± 33.457933.301 ± 51.7346
SecondaryAbsolute Change From Baseline in LVESVI at Month 3

Absolute change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · milliliter per square meter (mL/m^2)
Absolute Change From Baseline in LVESVI at Month 3
milliliter per square meter (mL/m^2)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in LVESVI at Month 3-2.881 ± 10.0057-4.743 ± 10.0689-4.741 ± 9.3632
SecondaryAbsolute Change From Baseline in LVESVI at Month 6

Absolute change from baseline in LVESVI at month 6 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · mL/m^2
Absolute Change From Baseline in LVESVI at Month 6
mL/m^2PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in LVESVI at Month 6-3.251 ± 11.1720-4.364 ± 11.9719-4.620 ± 9.7796
SecondaryAbsolute Change From Baseline in LVESVI at Month 12

Absolute change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · mL/m^2
Absolute Change From Baseline in LVESVI at Month 12
mL/m^2PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in LVESVI at Month 12-3.556 ± 12.9191-2.934 ± 13.8075-5.835 ± 12.7819
SecondaryRelative Change From Baseline in LVESVI at Month 3

Relative change from baseline in LVESVI at month 3 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · Percentage change in LVESVI
Relative Change From Baseline in LVESVI at Month 3
Percentage change in LVESVIPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in LVESVI at Month 3-6.750 ± 21.5157-9.592 ± 17.6281-9.916 ± 18.6656
SecondaryRelative Change From Baseline in LVESVI at Month 12

Relative change from baseline in LVESVI at month 12 is presented. LVESVI is considered one of the standard ECHO markers for assessing risks in ischemic HF. The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Percentage change in LVESVI
Relative Change From Baseline in LVESVI at Month 12
Percentage change in LVESVIPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in LVESVI at Month 12-7.595 ± 27.1199-3.977 ± 26.1962-11.340 ± 25.2110
SecondaryAbsolute Change From Baseline in Troponin T at Month 3

Absolute change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by high-sensitivity cardiac troponin (hs-cTn) assays.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · nanograms per liter (ng/L)
Absolute Change From Baseline in Troponin T at Month 3
nanograms per liter (ng/L)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Troponin T at Month 3-491.170 ± 1048.4929-614.101 ± 1191.9920-635.094 ± 1069.5844
SecondaryAbsolute Change From Baseline in Troponin T at Month 6

Absolute change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · ng/L
Absolute Change From Baseline in Troponin T at Month 6
ng/LPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Troponin T at Month 6-495.783 ± 1049.7521-616.713 ± 1192.9610-648.956 ± 1059.8187
SecondaryAbsolute Change From Baseline in Troponin T at Month 12

Absolute change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · ng/L
Absolute Change From Baseline in Troponin T at Month 12
ng/LPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Troponin T at Month 12-532.980 ± 1092.3140-597.288 ± 1202.6642-669.203 ± 1089.2607
SecondaryRelative Change From Baseline in Troponin T at Month 3

Relative change from baseline in troponin T at month 3 is presented. Troponin T levels were measured by hs-cTn assays.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · Percentage change in troponin T
Relative Change From Baseline in Troponin T at Month 3
Percentage change in troponin TPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in Troponin T at Month 3-70.517 ± 41.4856-70.113 ± 48.7907-65.982 ± 141.6371
SecondaryRelative Change From Baseline in Troponin T at Month 6

Relative change from baseline in troponin T at month 6 is presented. Troponin T levels were measured by hs-cTn assays.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Percentage change in troponin T
Relative Change From Baseline in Troponin T at Month 6
Percentage change in troponin TPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in Troponin T at Month 6-73.433 ± 38.5429-67.927 ± 101.6616-82.391 ± 26.2483
SecondaryRelative Change From Baseline in Troponin T at Month 12

Relative change from baseline in troponin T at month 12 is presented. Troponin T levels were measured by hs-cTn assays.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Percentage change in troponin T
Relative Change From Baseline in Troponin T at Month 12
Percentage change in troponin TPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in Troponin T at Month 12-78.753 ± 35.1892-78.671 ± 32.7166-83.657 ± 26.1048
SecondaryAbsolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1

Absolute change from baseline in NT-proBNP at month 1 is presented.

Time frame:
Baseline (Day 1), Month 1
Reported as:
Mean · picograms per milliliter (pg/mL)
Absolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1
picograms per milliliter (pg/mL)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Month 1-0.1444 ± 0.62513-0.1892 ± 0.48722-0.1384 ± 0.56701
SecondaryAbsolute Change From Baseline in NT-proBNP at Month 2

Absolute change from baseline in NT-proBNP at month 2 is presented.

Time frame:
Baseline (Day 1), Month 2
Reported as:
Mean · pg/mL
Absolute Change From Baseline in NT-proBNP at Month 2
pg/mLPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in NT-proBNP at Month 2-0.5252 ± 0.70912-0.6387 ± 0.67982-0.5467 ± 0.65068
SecondaryAbsolute Change From Baseline in NT-proBNP at Month 3

Absolute change from baseline in NT-proBNP at month 3 is presented.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · pg/mL
Absolute Change From Baseline in NT-proBNP at Month 3
pg/mLPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in NT-proBNP at Month 3-0.7991 ± 0.80655-0.8523 ± 0.78089-0.7210 ± 0.77963
SecondaryAbsolute Change From Baseline in NT-proBNP at Month 6

Absolute change from baseline in NT-proBNP at month 6 is presented.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · pg/mL
Absolute Change From Baseline in NT-proBNP at Month 6
pg/mLPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in NT-proBNP at Month 6-1.1076 ± 0.87256-1.1231 ± 0.90866-0.9706 ± 0.87285
SecondaryAbsolute Change From Baseline in NT-proBNP at Month 12

Absolute change from baseline in NT-proBNP at month 12 is presented.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · pg/mL
Absolute Change From Baseline in NT-proBNP at Month 12
pg/mLPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in NT-proBNP at Month 12-1.2172 ± 0.94119-1.4541 ± 1.00285-1.2894 ± 0.86983
SecondaryRelative Change From Baseline in NT-proBNP at Month 1

Relative change from baseline in NT-proBNP at month 1 is presented.

Time frame:
Baseline (Day 1), Month 1
Reported as:
Mean · Percentage change in NT-proBNP
Relative Change From Baseline in NT-proBNP at Month 1
Percentage change in NT-proBNPPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in NT-proBNP at Month 1-1.6895 ± 8.90865-2.5174 ± 6.72629-1.6953 ± 8.30762
SecondaryRelative Change From Baseline in NT-proBNP at Month 2

Relative change from baseline in NT-proBNP at month 2 is presented.

Time frame:
Baseline (Day 1), Month 2
Reported as:
Mean · Percentage change in NT-proBNP
Relative Change From Baseline in NT-proBNP at Month 2
Percentage change in NT-proBNPPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in NT-proBNP at Month 2-7.1409 ± 10.09998-8.6990 ± 9.09517-7.5912 ± 9.44475
SecondaryRelative Change From Baseline in NT-proBNP at Month 3

Relative change from baseline in NT-proBNP at month 3 is presented.

Time frame:
Baseline (Day 1), Month 3
Reported as:
Mean · Percentage change in NT-proBNP
Relative Change From Baseline in NT-proBNP at Month 3
Percentage change in NT-proBNPPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in NT-proBNP at Month 3-10.9714 ± 10.91364-11.5696 ± 10.50248-9.9554 ± 11.20355
SecondaryRelative Change From Baseline in NT-proBNP at Month 6

Relative change from baseline in NT-proBNP at month 6 is presented.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Percentage change in NT-proBNP
Relative Change From Baseline in NT-proBNP at Month 6
Percentage change in NT-proBNPPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in NT-proBNP at Month 6-15.3272 ± 11.68935-15.3277 ± 12.20384-13.3489 ± 12.89651
SecondaryRelative Change From Baseline in NT-proBNP at Month 12

Relative change from baseline in NT-proBNP at month 12 is presented.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Percentage change in NT-proBNP
Relative Change From Baseline in NT-proBNP at Month 12
Percentage change in NT-proBNPPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Relative Change From Baseline in NT-proBNP at Month 12-16.7190 ± 12.91568-19.4944 ± 12.52067-17.9837 ± 11.88971
SecondaryAbsolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 6

Absolute change from baseline in mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score (overall summary score) at month 6 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Sum-mary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 6
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 611.698 ± 18.34757.821 ± 21.50327.638 ± 19.1797
SecondaryAbsolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 12

Absolute change from baseline in mean KCCQ score (overall summary score) at month 12 is presented. The KCCQ is a 23-item, self-administered ques-tionnaire developed to independently measure the participant's perception of their health status. Scores range from 0 to 100, with 0 as lowest score and 100 as the highest score. Higher scores indi-cate better health status, fewer symptoms, and greater disease-specific health-related quality of life. The calculation is following the KCCQ scoring manual that states: "Overall Summary Score is defined as mean of the following available summary scores: Physical Limitation Score, Total Symptom Score, Quality of Life Score and Social Limitation Score". Because the manual states that the Overall Summary Score should be calculated on available scores, then if physical limitation score is missing, but other sub scores are available the Overall Summary Score will be calculated anyhow based on other sub scores.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 12
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in Mean KCCQ Score (Overall Summary Score) at Month 1212.349 ± 20.945710.255 ± 20.72948.261 ± 19.3870
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 6

Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 6
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 69.77 ± 18.8155.98 ± 20.4626.14 ± 19.981
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 12

Absolute change from baseline in KCCQ subdomain score (symptom burden) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Symptom burden: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 12
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Symptom Burden) at Month 129.90 ± 19.6718.24 ± 19.3096.37 ± 18.719
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 6

Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 6
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 68.46 ± 20.6487.59 ± 21.8764.37 ± 24.093
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 12

Absolute change from baseline in KCCQ subdomain score (physical limitation) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Physical limitation: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 12
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Physical Limitation) at Month 128.16 ± 22.0148.91 ± 23.0385.25 ± 22.807
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 6

Absolute change from baseline in KCCQ subdomain score (quality of life) at month 6 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 6
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 616.09 ± 24.37210.37 ± 27.73211.93 ± 23.116
SecondaryAbsolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 12

Absolute change from baseline in KCCQ subdomain score (quality of life) at month 12 is presented. The KCCQ is a 23-item, self-administered questionnaire developed to independently measure the participant's perception of their health status, which includes HF symptoms, impact on physical and social function, and how their HF impacts their quality of life within a 2-week recall period. The 7 domains under KCCQ include: Physical Limitation (6 items), Symptom Stability (1 item), Symptom Frequency (4 items), Symptom Burden (3 items), Self-Efficacy (2 items), Quality of Life (3 items), Social Limitations (4 items). Quality of life: scores on a scale of 0 to 100, higher scores means better outcome.

Time frame:
Baseline (Day 1), Month 12
Reported as:
Mean · Score on a scale
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 12
Score on a scalePlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Absolute Change From Baseline in KCCQ Subdomain Score (Quality of Life) at Month 1217.60 ± 26.81513.58 ± 27.49712.45 ± 25.473
PrimaryPercent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6

Percent change from baseline in LVESVI at Month 6 is presented. LVESVI is considered one of the standard echocardiography (ECHO) markers for assessing risks in ischemic heart failure (HF). The ECHO was performed to assess LVESVI.

Time frame:
Baseline (Day 1), Month 6
Reported as:
Mean · Percentage change in LVESVI
Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6
Percentage change in LVESVIPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6-7.611 ± 23.8747-8.364 ± 19.8437-9.824 ± 19.6001
Statistical analysis
  • Placebo vs CDR132L 10 mg/kg · ANCOVA · p = 0.257 · Ls mean difference: -2.138 · 95% CI -8.595 to 4.320
  • Placebo vs CDR132L 5 mg/kg · ANCOVA · p = 0.371 · Ls mean difference: -1.113 · 95% CI -7.769 to 5.543

Adverse events

Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo5/98 (5.1%)9/91 (9.9%)3/91 (3.3%)
CDR132L 5 mg/kg0/98 (0%)9/94 (9.6%)5/94 (5.3%)
CDR132L 10 mg/kg1/98 (1%)8/95 (8.4%)4/95 (4.2%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
Cardiac arrestCardiac disorders2/910/940/95
Cardiac failureCardiac disorders1/910/942/95
Acute coronary syndromeCardiac disorders1/910/940/95
Cardiorenal syndromeCardiac disorders1/910/940/95
Coronary artery stenosisCardiac disorders1/911/940/95
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/910/940/95
Non-cardiac chest painGeneral disorders1/911/940/95
Renal failureRenal and urinary disorders1/910/941/95
Urinary tract infectionInfections and infestations1/910/940/95
Acute myocardial infarctionCardiac disorders0/911/940/95
Most frequent other events
Most frequent other events
EventPlaceboCDR132L 5 mg/kgCDR132L 10 mg/kg
NasopharyngitisInfections and infestations3/915/944/95

Baseline characteristics

A modified Intent-to-Treat (mITT) analysis set has been defined to include all randomized subjects who receive at least 1 dose of study drug (CDR132L or placebo).

Age, Continuous
Age, Continuous(Years)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kgTotal
Mean61.0 ± 10.4460.8 ± 10.1261.0 ± 10.1160.9 ± 10.18
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kgTotal
Female9111535
Male818381245
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCDR132L 5 mg/kgCDR132L 10 mg/kgTotal
American Indian or Alaska Native0000
Asian1214
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White889091269
More than one race0000
Unknown or Not Reported0145
08

Study locations

49 sites
  • Institut klinicke a experimentalni mediciny
    Prague, Czechia
  • Všeobecná fakultní nemocnice v Praze
    Prague, Czechia
  • St. Marien-Krankenhaus Ahaus
    Ahaus, Germany
  • Herzzentrum Dresden Universitätsklinik
    Dresden, Germany
  • Helios Klinikum Erfurt
    Erfurt, Germany
  • Universitätsmedizin Göttingen
    Göttingen, Germany
  • Medizinische Hochschule Hannover
    Hanover, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Klinikum Ludwigshafen
    Ludwigshafen, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Germany
  • "Alexandra" General Hospital of Athens
    Athens, Greece
  • "Attikon" General University Hospital
    Athens, Greece
  • General University Hospital of Patras "Panagia i Voitheia"
    Pátrai, Greece
  • Semmelweis University
    Budapest, Hungary
  • Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch
    's-Hertogenbosch, Netherlands
  • Deventer Ziekenhuis
    Deventer, Netherlands
  • Slingeland Ziekenhuis
    Doetinchem, Netherlands
  • Gelderse Vallei Ziekenhuis
    Ede, Netherlands
  • Medisch Centrum Leeuwarden
    Leeuwarden, Netherlands
  • St. Jansdal Ziekenhuis
    Lelystad, Netherlands
  • Erasmus University Medical Center
    Rotterdam, Netherlands
  • Ikazia Ziekenhuis
    Rotterdam, Netherlands
  • D & A Research B.V.
    Sneek, Netherlands
  • Gelre Ziekenhuizen
    Zutphen, Netherlands
  • Polsko Amerykanskie Kliniki Serca
    Kędzierzyn-Koźle, Poland
  • Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego
    Kielce, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawla II
    Krakow, Poland
  • Gabinet Internistyczno-Kardiologiczny Jacek Nowak
    Libiąż, Poland
  • NZOZ SALUS JZ Peruga
    Lodz, Poland
  • One wojskowy Szpital Kliniczny w Lublinie
    Lublin, Poland
  • Medicome Sp. z o.o.
    Oświęcim, Poland
  • Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu
    Przemyśl, Poland
  • NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog
    Sopot, Poland
  • Wojewodzki Szpital Zespolony
    Torun, Poland
  • Spec.Szpital im.dr Sokolowskiego
    Wałbrzych, Poland
  • Investigational Site
    Wroclaw, Poland
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, Spain
  • Hospital Universitario San Cecilio
    Granada, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Hospital Universitario de Sabadell
    Sabadell, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, Spain
  • Complejo Hospitalario Universitario de Vigo
    Vigo, Spain
  • Queen Elizabeth University Hospital
    Glasgow, United Kingdom
  • Wycombe Hospital
    High Wycombe, United Kingdom
  • Richmond Pharmacology Limited
    London, United Kingdom
  • South Tees Hospital NHS Foundation Trust
    Middlesbrough, United Kingdom
09

References and documents

Publications

  • Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, de Boer RA, Filippatos G, Friede T, Hauke W, Ponikowski P, Vardeny O, Altschul R, Gamborg M, Vinther K, Thum T. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial. Nat Med. 2026 Jul;32(7):2654-2661. doi: 10.1038/s41591-026-04408-4. Epub 2026 May 10. PubMed 42108271 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Sep 2024, 26 months.

Results were first posted in Aug 2026, 1 year 11 months after primary completion. A results delay was requested in Jan 2025.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 28, 2022
StartActual
Jul 11, 2022
Primary completionActual
Sep 26, 2024
CompletionActual
Mar 17, 2025
Results delay requested
Jan 15, 2025
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05350969
Responsible party
Sponsor
First posted
Apr 28, 2022
Start date
Jul 11, 2022
Primary completion
Sep 26, 2024
Completion
Mar 17, 2025
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Study contacts

Johann Bauersachs, Prof. Dr.
principal investigator · Hannover Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDR132L

Start the discussion